Emergency reversal of antithrombotic treatment

被引:36
作者
Levi, Marcel [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Med F4, NL-1105 AZ Amsterdam, Netherlands
关键词
Anticoagulants; Hemorrhage; Heparin; Pentasaccharides; Vitamin K antagonists; Aspirin; Clopidogrel; IIb-IIIa inhibitors; PROTHROMBIN COMPLEX CONCENTRATE; RECOMBINANT FACTOR VIIA; INTERNATIONAL NORMALIZED RATIO; MOLECULAR-WEIGHT HEPARIN; ACUTE CORONARY SYNDROMES; ACTIVATED FACTOR-VII; COUMARIN-ASSOCIATED COAGULOPATHY; THROMBIN INHIBITOR XIMELAGATRAN; ANTICOAGULANT PROTEIN C2; TOTAL KNEE REPLACEMENT;
D O I
10.1007/s11739-008-0201-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The most important adverse effect of antithrombotic treatment is the occurrence of bleeding. In case of serious or even life-threatening bleeding in a patient who uses anticoagulant agents or when a patient on anticoagulants needs to undergo an urgent invasive procedure, anticoagulant treatment can be reversed by various specific strategies. Heparin and heparin derivatives can be counteracted by protamine sulphate, whereas the anticoagulant effect of vitamin K antagonists may be neutralized by administration of vitamin K or prothrombin complex concentrates. The anti-hemostatic effect of aspirin and other anti-platelet strategies can be corrected by the administration of platelet concentrate or desmopressin, if needed. Recently, a new generation of anticoagulants with a greater specificity towards activated coagulation factors has been introduced and most of these agents are presently being evaluated in clinical studies. The new generation anticoagulants include specific inhibitors of factor IIa, factor Xa (including pentasaccharides) and agents that interfere with tissue factor activity. A limitation of this new class of anticoagulants may be the lack of an appropriate strategy to reverse the effect if a bleeding event occurs, although in some cases the administration of recombinant factor VIIa may be an option.
引用
收藏
页码:137 / 145
页数:9
相关论文
共 77 条
[61]  
Shantsila E, 2008, CURR OPIN INVEST DR, V9, P1020
[62]   Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects [J].
Sorensen, B ;
Johansen, P ;
Nielsen, GL ;
Sorensen, JC ;
Ingerslev, J .
BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (05) :469-477
[63]   Anticoagulant repertoire of the hookworm Ancylostoma caninum [J].
Stanssens, P ;
Bergum, PW ;
Gansemans, Y ;
Jespers, L ;
Laroche, Y ;
Huang, S ;
Maki, S ;
Messens, J ;
Lauwereys, M ;
Cappello, M ;
Hotez, PJ ;
Lasters, I ;
Vlasuk, GP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (05) :2149-2154
[64]   Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? [J].
Strebel, N ;
Prins, M ;
Agnelli, G ;
Büller, HR .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (13) :1451-1456
[65]   Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device - An alternative to protamine [J].
Tao, W ;
Deyo, DJ ;
Brunston, RL ;
Vertrees, RA ;
Zwischenberger, JB .
CRITICAL CARE MEDICINE, 1998, 26 (06) :1096-1102
[66]  
VAN AL, 2006, THROMB RES, V118, P313
[67]   Invasive procedures in the outpatient setting:: Managing the short-acting acenocoumarol and the long-acting phenprocoumon [J].
van Geest-Daalderop, Johanna H. H. ;
Hutten, BarbaraA. ;
Pequeriaux, Nathalie C. V. ;
de Vries-Goldschmeding, Hanneke J. ;
Rakers, Emmy ;
Levi, Marcel .
THROMBOSIS AND HAEMOSTASIS, 2007, 98 (04) :747-755
[68]  
VANRYNMCKENNA J, 1990, THROMB HAEMOSTASIS, V63, P271
[69]   Normalization of platelet reactivity in clopidogrel-treated subjects [J].
Vilahur, G. ;
Choi, B. G. ;
Zafar, M. U. ;
Viles-Gonzalez, J. F. ;
Vorchheimer, D. A. ;
Fuster, V. ;
Badimon, J. J. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (01) :82-90
[70]   Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis [J].
Wåhlander, K ;
Lapidus, L ;
Olsson, CG ;
Thuresson, A ;
Eriksson, UG ;
Larson, G ;
Eriksson, H .
THROMBOSIS RESEARCH, 2002, 107 (3-4) :93-99